Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 26;12(7):2503.
doi: 10.3390/jcm12072503.

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Ahmad Albshesh  1   2 , Lian Bannon  2   3 , Tali Sharar Fischler  4 , Marie Truyens  5 , Stephan R Vavricka  6 , Katja Tepes  7 , Daniela Pugliese  8 , Edoardo V Savarino  9 , Eran Zittan  10   11 , David Drobne  12   13 , Xavier Roblin  14 , Ariella Bar-Gil Shitrit  15   16 , Alessandro Armuzzi  17   18 , Triana Lobaton  5 , Nitsan Maharshak  2   3 , Henit Yanai  2   4 , Shomron Ben-Horin  1   2 , Uri Kopylov  1   2
Affiliations

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Ahmad Albshesh et al. J Clin Med. .

Abstract

Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described.

Aims and methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn's disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16-22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events.

Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16-22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6).

Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line.

Keywords: Crohn’s disease; anti-TNF; drug positioning; treatment failure; treatment response; ustekinumab; vedolizumab.

PubMed Disclaimer

Conflict of interest statement

Ahmad Albshesh—received speaking fees from Takeda; Stephan Vavricka—has received consulting fees, speakers honorary and unrestricted research grants from Abbott, Alfasigma, Amgen, Arenapharm, Falk Pharma GmbH, Ferring Pharmaceuticals, Gilead, iQuone, Janssen, MSD, Permamed, Pfizer Inc, Sanofi-Aventis, Takeda, Tillotts, UCB, and Vifor; Eran Zittan—received research support and consulting fees from Janssen, AbbVie, Takeda, Neopharm, Celgene and Pfizer; David Drobne—has served as a speaker, a consultant and an advisory board member for MSD, Abbvie, Takeda, Pfizer, Janssen, and Krka; Alessandro Armuzzi—consulting, advisory board and/or lecture fees and/or research support: AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Novartis, Pfizer, Protagonist-Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda; Triana lobaton—Financial support for research from Abbvie, Viatris, MSD, Mundipharma, Biogen, Janssen, Pfizer and Takeda; Speaker fees from Ferring, MSD, Abbvie, Janssen, Amgen, Fresenius Kabi, Galapagos, Viatrisand Takeda; Consultancy fee from Janssen, Galapagos, Amgen, Bristol Myers Squibb Fresenius Kabiand Takeda; Nitsan Maharshak—has received speaking and/or consulting fees from Pfizer, Takeda, Janssen, Ferring, BiomX, BMS, Nestle and grant support from Takeda, Janssen, Abbott, Abbvie, Pfizer, BMS, Nestle, Trobix; Henit Yanai: reports institutional research grants from Pfizer and the ISF; consulting fees from Abbvie, Janssen, Pfizer, and Takeda; honoraria for lectures from Abbvie, Janssen, Pfizer, and Takeda; participation in a Data Safety Monitoring Board or Advisory Board from Abbvie, Pfizer, and Takeda; Shomron Ben-Horin—consulting and advisory board fees and/or research support—Abbvie, MSD, Janssen, Takeda, and CellTrion; Uri Kopylov—research support- Jannsen Medtronic Takeda, advisory and speaker fees- Abbvie BMS Janssen Medtronic Novartis Pfizer Takeda. All other authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Chart of the patients’ flow during the study period. Abbreviations: CD, Crohn’s disease; anti-TNF, anti-Tumor Necrosis Factor; UST, ustekinumab.
Figure 2
Figure 2
Outcomes in the initial (A) and maintenance period (B). The proportion of patients achieving clinical remission (HBI ≤ 4), clinical response (delta HBI ≥ 3) and steroid-free remission during the initial period (week 16–22) (A), and the proportion of patients achieving clinical remission, clinical response and steroid free remission during the maintenance period (week 52) (B); HBI: Harvey–Bradshaw index; UST: ustekinumab; anti-TNF: anti-tumor necrosis factor.
Figure 3
Figure 3
Biomarker normalization. The proportion of patients with CRP normalization (A) (CRP serum concentration levels less than normal range as per cut-off used in the corresponding institutions) and FCP normalization (B) (FCP < 250 µg/g); CRP, C-reactive protein; FCP, Fecal Calprotectin; UST, ustekinumab; anti-TNF, anti-tumor necrosis factor.
Figure 4
Figure 4
Cox regression test of treatment discontinuation-free analysis; UST1, ustekinumab; TNF2, anti-tumor necrosis factor; HR, hazard ratio; CI, confidence interval; p, p-value.
See this image and copyright information in PMC

References

    1. Dreesen E., Gils A. Letter: Overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors’ reply. Aliment. Pharmacol. Ther. 2018;48:1029–1030. doi: 10.1111/apt.14974. - DOI - PubMed
    1. Kopylov U., Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Ther. Adv. Gastroenterol. 2016;9:513–526. doi: 10.1177/1756283X16638833. - DOI - PMC - PubMed
    1. Stidham R.W., Lee T.C.H., Higgins P.D.R., Deshpande A.R., Sussman D.A., Singal A.G., Elmunzer B.J., Saini S.D., Vijan S., Waljee A.K. Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment. Pharmacol. Ther. 2014;39:1349–1362. doi: 10.1111/apt.12749. - DOI - PMC - PubMed
    1. Preda C., Fulger L.E., Gheorghe L., Gheorghe C., Goldis A., Trifan A., Tantau M., Tantau A., Negreanu L., Manuc M., et al. Infliximab and Adalimumab in Crohn’s disease: Real-life data from a national cohort study. Curr. Health Sci. J. 2016;42:115–124. - PMC - PubMed
    1. Stidham R.W., Lee T.C.H., Higgins P.D.R., Deshpande A.R., Sussman D.A., Singal A.G., Waljee A.K. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–627.e3. - PubMed